bioRxiv Science⌕ Search

bioRxiv · 10.1101/2025.06.24.661057

Profiling Lysosomal and Mitochondrial Dysfunction in Neurodegenerative Diseases Using Human Fibroblasts for Translational Therapeutic Screening

Abstract

Lysosomal dysfunction and mitochondrial health are intricately connected, playing essential roles in cellular homeostasis. Lysosomes are acidic membrane-bound organelles responsible for degrading and recycling cellular waste, while mitochondria generate the energy required for cellular functions. Growing evidence implicates roles for lysosomal and mitochondrial dysfunction in neurodegenerative diseases, including Alzheimers and Parkinsons disease. With novel therapeutics targeting both the lysosomal and mitochondrial functions, robust assays for compound screening are becoming critical to evaluate modulation of both organelles in disease-relevant cellular models. Here, we investigated human fibroblasts derived from healthy donors, as well as patients with Alzheimers and Parkinsons disease, to assess their capacity to model key aspects of lysosomal and mitochondrial dysfunction. Lysosomal function was evaluated using various assays, including quantification of lysosomal proteins (TMEM175 and LAMP1), LysoTracker staining, measurement of lysosomal pH, and lysosomal enzymatic activity. Autophagic flux was assessed by measuring p62 levels as a marker of autophagy. Mitochondrial function was investigated by measuring mitochondrial calcium levels, membrane potential, oxidative stress, and mitochondrial content using MitoTracker. To explore the potential of using human fibroblasts for in vitro compound screening, we validated these assays in a 384-well high-throughput format using compounds such as chloroquine and ammonium chloride. Our findings demonstrate that human fibroblasts faithfully recapitulate lysosomal and mitochondrial dysfunctions characteristic of neurodegenerative diseases. Moreover, the use of robust assays positions these cells as a valuable platform for high-throughput screening to identify novel therapeutics targeting lysosomal and mitochondrial pathways.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Leite, D. M., Lenham, R., Malko, P., Thomson, S., Phillips, T., Rosenstock, T. R., Mirza, N. R.. 2025-06-25. Profiling Lysosomal and Mitochondrial Dysfunction in Neurodegenerative Diseases Using Human Fibroblasts for Translational Therapeutic Screening. https://doi.org/10.1101/2025.06.24.661057

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

The Unreasonable Effectiveness of Cell Types in Describing Neuronal Physiological Features

Single-cell RNA sequencing (scRNA-seq) captures detailed gene expression profiles at scale, while patch-clamp recordings measure intrinsic neuronal electrophysiological properties. Modeling the relations between these two modalities remains a challenge. Here, we compare how well electrophysiological features can be predicted by traditional transcriptomic cell type classification, representations derived from a foundational model (scGPT) pretrained on large-scale scRNA-seq datasets, ion channel-coding genes, and highly variable genes. Using paired transcriptomic and electrophysiological patch-sequencing data from 495 human neurons from neurosurgical tissue, we find that cluster-level cell type representations consistently outperform highly variable gene selection, ion channel gene selection, and context-enriched scGPT embeddings. Notably, performance varies across model architectures and initializations, and the best results are obtained by combining the outputs of separate cell type and scGPT-based models. Together, these findings suggest that traditional discrete cellular classification is highly effective in predicting physiological features. For maximum performance it can be complemented by pretrained transformer models.

neuroscience↗

A nonlinear inhibition pathway underlying cortical responses to tuned holographic optogenetic perturbations

Optogenetics enables causal manipulation of cortical activity. Perturbation responses can be counterintuitive due to network interactions, making theory essential for predicting them. Existing approaches often rely on linear approximations, which fail for many biologically relevant perturbations. Here we develop a nonlinear theory of responses to holographic perturbations in cell-type-specific recurrent networks with structured connectivity. We fit a nonlinear model to mouse V1 data, which shows cotuned-ensemble suppression: perturbing spatially clustered neurons with similar preferred orientations yields markedly stronger short-range suppression than perturbing untuned ensembles. We show that cotuned-ensemble suppression arises from a feature-tuned, nonlinear inhibition pathway implicating somatostatin-positive (SST) interneurons. The theory predicts that cotuned ensembles suppress parvalbumin-positive (PV) neurons but facilitate SST neurons, and links the degree of cotuned-ensemble suppression or facilitation to the variance of the SST response. This framework identifies mechanisms by which nonlinear inhibition sculpts cortical dynamics and establishes a predictive basis for targeted optogenetic interventions.

neuroscience↗

Proteomic signatures of APOE ε4 across human tissues and cell types in Alzheimers disease

The apolipoprotein E {varepsilon}4 (APOE {varepsilon}4) allele is the strongest genetic risk factor for late-onset Alzheimers disease (AD). However, the underlying molecular mechanisms remain unclear. This study included 1691 participants from the Religious Orders Study and Rush Memory and Aging Project (ROSMAP), 1226 participants from the Accelerating Medicines Partnership - Alzheimers Disease (AMP-AD) Diverse Cohorts Study, and 735 participants from the Alzheimers Disease Neuroimaging Initiative (ADNI). To characterise APOE {varepsilon}4 molecular effects, we analysed proteomic data from plasma, cerebrospinal fluid (CSF), and induced pluripotent stem cell (iPSC)-derived astrocytes and neurons, as well as transcriptomic and proteomic data from multiple brain regions. The association of APOE {varepsilon}4 with AD neuropathology was also examined. APOE {varepsilon}4 carriers shared a plasma proteomic signature enriched for immune processes, irrespective of AD diagnosis. A machine learning classifier trained on this signature discriminated APOE {varepsilon}4 carriers from non-carriers in an independent cohort using CSF proteomics. APOE {varepsilon}4 carriage was associated with higher Braak stages and Consortium to Establish a Registry for Alzheimers Disease (CERAD) score. However, only limited APOE {varepsilon}4-associated transcriptomic and proteomic changes were observed in bulk brain tissue, with poor cross-layer concordance. Proteomic analyses of iPSC-derived astrocytes and neurons further revealed cell-type-specific APOE {varepsilon}4-associated changes. APOE {varepsilon}4 is associated with a consistent proteomic signature across plasma and CSF. Its molecular effects in the brain differ across cell types, brain regions and molecular layers. These findings support the need for cell-type-resolved multi-omic studies to elucidate how APOE {varepsilon}4 confers AD risk.

neuroscience↗